Equities

Biomx Inc

Biomx Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.40
  • Today's Change-0.018 / -4.31%
  • Shares traded300.74k
  • 1 Year change+11.11%
  • Beta1.3296
Data delayed at least 15 minutes, as of May 31 2024 21:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

  • Revenue in USD (TTM)0.00
  • Net income in USD-37.14m
  • Incorporated2017
  • Employees58.00
  • Location
    Biomx Inc22 Einstein St., Floor 4NESS-ZIONA 7414003IsraelISR
  • Phone+972 723942377
  • Fax+1 8 002535177
  • Websitehttps://www.biomx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PHGE:ASQ since
announced
Transaction
value
Adaptive Phage Therapeutics IncDeal completed06 Mar 202406 Mar 2024Deal completed73.91%2.11m
Data delayed at least 15 minutes, as of May 31 2024 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aprea Therapeutics Inc963.81k-12.72m25.90m7.00--0.8955--26.87-3.32-3.320.25035.570.0296----137,687.10-39.00-68.66-43.83-77.19-----1,319.45-42,112.84----0.00------87.32--90.61--
Unity Biotechnology Inc0.00-34.78m26.02m19.00--1.08-----2.33-2.330.001.430.00----0.00-40.18-47.21-48.47-53.51-------6,395.92----0.00---100.00--10.36---61.28--
Singular Genomics Systems Inc2.49m-96.21m27.02m255.00--0.1724--10.85-1.31-1.310.0342.120.00910.23332.989,764.71-35.33---37.29---41.49---3,863.90--9.54--0.0614--280.52---4.34------
Alterola Biotech Inc0.00-2.88m27.17m1.00---------0.0027-0.00270.00-0.0010.00----0.00-47.24---63.88----------0.0019----------73.07------
Aptorum Group Ltd431.38k-2.82m27.25m3.00--1.04--63.16-0.9126-0.91260.09544.800.020830.363.88143,793.30-20.92-40.45-19.62-42.362.45-4.04-1,006.30-1,233.681.18--0.1694---66.712.3871.18---78.15--
Oncternal Therapeutics Inc1.15m-36.38m27.26m27.00--1.19--23.68-12.35-12.350.39077.750.0263----42,629.63-83.23-49.40-95.97-54.51-----3,160.73-1,342.98----0.00---47.32--10.62------
Viracta Therapeutics Inc0.00-47.99m27.49m40.00--4.88-----1.24-1.240.000.28210.00----0.00-75.51-86.35-112.64-106.38-------11,853.94---84.180.6277-------3.78------
RenovoRx Inc0.00-8.05m27.78m8.00--11.07-----0.7249-0.72490.000.10480.00----0.00-172.23---231.65--------------0.00-------3.47------
BioVie Inc0.00-37.18m27.79m18.00--1.47-----0.9626-0.96260.000.31040.00----0.00-94.32-456.35-149.75-1,810.88------------0.2969-------92.67------
Biomx Inc0.00-37.14m27.92m58.00---------0.6234-0.62340.000.38130.00----0.00-60.38---72.74-------------2.250.00------7.59------
bioAffinity Technologies Inc4.94m-8.37m27.98m75.00--5.12--5.67-0.9197-0.91970.54160.46870.5334318.228.7065,839.60-90.38---104.93--32.88---169.42--2.21--0.1782--52,660.42--2.66------
NanoViricides Inc0.00-9.51m28.35m7.00--2.66-----0.8115-0.81150.000.90170.00----0.00-63.30-43.54-65.85-46.29------------0.00-------5.94---8.90--
Qilian International Holding Group Ltd46.47m-7.78m28.60m298.00--0.6684--0.6154-0.2176-0.21761.301.200.80276.4533.30155,944.60-14.032.71-16.843.863.7711.66-17.482.724.43-0.48120.010726.11-28.35-1.60-822.64--12.86--
Bolt Biotherapeutics Inc11.32m-63.03m28.85m100.00--0.277--2.55-1.66-1.660.29872.730.0649----113,240.00-36.11-48.32-39.88-54.03-----556.59-2,267.00----0.00--37.48--21.45---6.61--
Palatin Technologies, Inc.5.90m-32.20m29.05m34.00--18.40--4.92-2.39-2.390.42750.09790.31890.64026.95173,588.80-173.98-26.11-387.23-30.6896.58---545.58-126.201.20--0.0443--230.53-40.8723.91--80.82--
Data as of May 31 2024. Currency figures normalised to Biomx Inc's reporting currency: US Dollar USD

Institutional shareholders

0.24%Per cent of shares held by top holders
HolderShares% Held
Renaissance Technologies LLCas of 31 Mar 202480.60k0.15%
Millennium Management LLCas of 31 Mar 202419.76k0.04%
Jump Trading LLCas of 31 Mar 202419.21k0.04%
XTX Markets LLCas of 31 Mar 202410.19k0.02%
PNC Bank, NA (Investment Management)as of 31 Mar 20244.00k0.01%
Bank of America, NA (Private Banking)as of 31 Mar 20241.000.00%
MM Asset Management, Inc.as of 31 Mar 20240.000.00%
G1 Execution Services LLCas of 31 Mar 20240.000.00%
Walleye Capital LLCas of 31 Mar 20240.000.00%
Bridgeway Capital Management LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.